Poliwogg Names Dennis Purcell as Special Advisor

Purcell will work with Poliwogg to identify and facilitate funding for innovative early stage health-related companies.

  • Share on TwitterShare on FacebookShare on Google+Share on LinkedInEmail a friend
No one understands the landscape of biotechnology and the evolution of biotechnology companies better than Dennis Purcell. His advice will help Poliwogg fill a much-needed role in funding early stage companies whose success will benefit us all.

San Francisco, CA (PRWEB) January 13, 2014

Poliwogg Holdings, Inc., an innovative financial firm transforming healthcare investing, today announced that it has named Dennis Purcell, Senior Managing Director of Aisling Capital and a leading figure in biotechnology investing, as a Special Advisor to Poliwogg. In his role as Special Advisor, Mr. Purcell will work with Poliwogg to identify and facilitate funding for innovative early stage health-related companies. Mr. Purcell is also a shareholder in Poliwogg.

"Dennis Purcell has been the face and the voice of investing in the future of biotechnology for several decades. All of us at Poliwogg are privileged to welcome him as a shareholder and a Special Advisor,” said Greg Simon, CEO of Poliwogg. “No one understands the landscape of biotechnology and the evolution of biotechnology companies better than Dennis Purcell. His advice will help Poliwogg fill a much-needed role in funding early stage companies whose success will benefit us all."

“As the health care industry evolves at an accelerating rate, the ways we fund this critical industry are rapidly evolving too,” said Mr. Purcell. “New sources of capital are playing an important role alongside traditional institutional investors and venture capitalists. The individual investor, in particular, is becoming more relevant to the funding of the sector. Poliwogg enables these investors to participate in funding the industry in a meaningful and efficient way. I expect Poliwogg and its network to play an important role in advancing the science that life science companies are developing and, thus, help bring important new therapies to patients.”

Mr. Purcell is currently the Senior Managing Director of Aisling Capital, a fund with approximately $1.7 billion of assets under management. Prior to joining Aisling Capital, Mr. Purcell served as Managing Director of the Life Sciences Investment Banking Group at Chase H&Q (formerly Hambrecht & Quist). While at H&Q, he was directly involved with over 200 completed transactions and supervised over $10 billion of financing and advisory assignments in the pharmaceutical, biotechnology, and medical products industries. Prior to H&Q, Mr. Purcell was a Managing Director in the Healthcare Group at PaineWebber, Inc.

Mr. Purcell also currently serves as a director of Paratek Pharmaceuticals, Inc. He has served as a member of the Advisory Council at Harvard Medical School, the Board of Directors of the Biotechnology Industry Association, as well as the New York Biotechnology Association and the Irvington Institute. He also serves on the Board of L.E.K. consulting.

About Aisling Capital

Aisling Capital is a leading investment firm that advises investment funds that invest in products, technologies, and global businesses that advance health.

Aisling Capital is led by a group of investment professionals with diverse backgrounds in industry, science, and finance. The team’s complementary backgrounds give Aisling Capital unique perspective on the key players, events, and forces shaping the life science industry, and allow the Fund to identify investment opportunities. In working with our portfolio companies, the principals of Aisling Capital seek to provide the financing, relationships, and guidance needed to build highly successful companies.

About Poliwogg

Poliwogg is an innovative financial firm transforming healthcare investing. We provide pathways for accredited investors to invest in early stage companies in health and life sciences, structure indexes that quantify the impact of public companies in health, and are launching sector specific publicly registered venture funds focused by health vertical. Our mission is to transform health from a cost to an asset class. For more information, visit http://www.poliwogg.com. Follow Poliwogg on Twitter @poliwoggpond, and on LinkedIn.

Media Contact:
Patty Buchanan
Fastlane Communications
(973) 670-1203
pbuchanan(at)fast-lane(dot)net

Poliwogg Contact:
Jeffrey Feldman, Director, Poliwogg Board
Poliwogg
(212) 370-0535
jfeldman(at)poliwogg(dot)com
http://www.poliwogg.com

Aisling Contact:
Carol Zikopoulos, Assistant to Dennis Purcell
Aisling Capital
(212) 651-6382
czikopoulos(at)aislingcapital(dot)com
http://www.aislingcapital.com

Private investment marketing and other broker-dealer services are currently offered through a partnership with SDDCO Brokerage Advisors, LLC, Member FINRA/SIPC (“SDDCO-BA”). All such services offered by Poliwogg-associated persons are done so in their capacities as registered representatives of SDDCO-BA. Poliwogg and its affiliates are independent and unaffiliated with SDDCO-BA.


Contact

  • Patty Buchanan
    Fastlane Communications
    +1 (973) 670-1203
    Email